Filtered By:
Condition: Stroke
Drug: Enalapril

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 61 results found since Jan 2013.

Effect of Vitamin B12 Levels on the Association Between Folic Acid Treatment and CKD Progression: A Post Hoc Analysis of a Folic Acid Interventional Trial
ConclusionsFolic acid treatment was associated with a greater reduction in the odds of CKD progression among patients with mild to moderate CKD and higher B12 levels.FundingGovernment funding (National Key Research and Development Program of China).
Source: American Journal of Kidney Diseases - October 17, 2019 Category: Urology & Nephrology Source Type: research

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Publication date: 24–30 August 2019Source: The Lancet, Volume 394, Issue 10199Author(s): Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi, Karla Hemming, Farin Kamangar, Abdolsamad Gharavi, Mohammad Reza Ostovaneh, Alireza Nateghi, Masoud Majed, Behrooz Navabakhsh, Shahin Merat, Akram Pourshams, Mahdi Nalini, Fatemeh Malekzadeh, Masoumeh Sadeghi, Noushin Mohammadifard, Nizal Sarrafzadegan, Mohammad Naemi-Tabiei, Abdolreza Fazel, Paul BrennanSummaryBackgroundA fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income ...
Source: The Lancet - August 23, 2019 Category: General Medicine Source Type: research

The modifying effect of the MTHFR genotype on the association between folic acid supplementation and pulse wave velocity: Findings from the CSPPT
ConclusionIn a subgroup of Chinese hypertensive patients who had received 5 ‐year antihypertensive therapy, increases in folate status were associated with higher reductions in PWV, and individuals with the CC genotype showed greatest PWV response to folic acid supplementation.
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Xin Yang, Minghua Zhang, Rensheng Song, Changfu Liu, Yong Huo, Geng Qian Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Plasma retinol and the risk of first stroke in hypertensive adults: a nested case-control study.
Conclusions: Our data showed a significant inverse association between plasma retinol and the risk of first stroke among Chinese hypertensive adults. This study was registered at clinicaltrials.gov as NCT00794885. PMID: 30624586 [PubMed - as supplied by publisher]
Source: The American Journal of Clinical Nutrition - January 9, 2019 Category: Nutrition Authors: Yu Y, Zhang H, Song Y, Lin T, Zhou Z, Guo H, Liu L, Wang B, Liu C, Li J, Zhang Y, Huo Y, Wang C, Wang X, Hou FF, Qin X, Xu X Tags: Am J Clin Nutr Source Type: research

The modifying effect of the MTHFR genotype on the association between folic acid supplementation and pulse wave velocity: Findings from the CSPPT
ConclusionIn a subgroup of Chinese hypertensive patients who had received 5 ‐year antihypertensive therapy, increases in folate status were associated with higher reductions in PWV, and individuals with the CC genotype showed greatest PWV response to folic acid supplementation.
Source: Cardiovascular Therapeutics - November 20, 2018 Category: Cardiology Authors: Xin Yang, Minghua Zhang, Rensheng Song, Changfu Liu, Yong Huo, Geng Qian Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Hypertensive patients may benefit from folic acid supplements
Hypertensive adults with low platelet count who took a combined daily pill of both enalapril and folic acid saw a 73 percent reduction in their risk of first stroke compared to patients who took only enalapril daily, according to a study published in the Journal of the American College of Cardiology.
Source: World Pharma News - May 8, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Effect of Smoking and Folate Levels on the Efficacy of Folic Acid Therapy in Prevention of Stroke in Hypertensive Men Clinical Sciences
Conclusions—Baseline folate levels and smoking status can interactively affect the risk of first stroke. Our data suggest that compared with never smokers, ever smokers may require a higher dosage of folic acid to achieve a greater beneficial effect on stroke. Our findings need to be confirmed by future randomized trials.Clinical Trial Registration—URL: https://www.clinicaltrials.gov. Unique identifier: NCT00794885.
Source: Stroke - December 22, 2017 Category: Neurology Authors: Ziyi Zhou, Jianping Li, Yaren Yu, Youbao Li, Yan Zhang, Lishun Liu, Yun Song, Min Zhao, Yu Wang, Genfu Tang, Mingli He, Xiping Xu, Yefeng Cai, Qiang Dong, Delu Yin, Xiao Huang, Xiaoshu Cheng, Binyan Wang, Fan Fan Hou, Xiaobin Wang, Xianhui Qin, Yong Huo Tags: Primary Prevention, Hypertension, Treatment, Cerebrovascular Disease/Stroke Original Contributions Source Type: research

Homocysteine-lowering interventions for preventing cardiovascular events.
CONCLUSIONS: In this third update of the Cochrane review, there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination comparing with placebo on myocardial infarction, death from any cause or adverse events. In terms of stroke, this review found a small difference in effect favouring to homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination comparing with placebo.There were uncertain effects of enalapril plus folic acid compared with enalapril on stroke; approxima...
Source: Cochrane Database of Systematic Reviews - August 17, 2017 Category: General Medicine Authors: Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M Tags: Cochrane Database Syst Rev Source Type: research

Effects of Folic Acid Therapy on the New-Onset Proteinuria in Chinese Hypertensive PatientsNovelty and Significance Clinical Trials
In conclusion, enalapril–folic acid therapy, compared with enalapril alone, significantly reduced the development of proteinuria in diabetic patients with hypertension.Clinical Trial Registration—URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00794885.
Source: Hypertension - July 12, 2017 Category: Cardiology Authors: Youbao Li, Min Liang, Guobao Wang, Binyan Wang, Mingli He, Genfu Tang, Delu Yin, Xin Xu, Yong Huo, Yimin Cui, Fan Fan Hou, Xianhui Qin Tags: Clinical Studies, Diabetes, Type 1, Diet and Nutrition, Hypertension Original Articles Source Type: research

Folic acid therapy reduces the risk of mortality associated with heavy proteinuria among hypertensive patients
Objective: We aimed to evaluate whether proteinuria and estimated glomerular filtration rate (eGFR) levels can modify the efficacy of folic acid therapy on the risk of all-cause mortality among hypertensive patients in the China Stroke Primary Prevention Trial, a randomized, double-blind, and controlled trial. Methods: A total of 20 702 hypertensive patients without a history of major cardiovascular diseases were randomly assigned to a double-blind daily treatment of a single tablet containing 10-mg enalapril and 0.8-mg folic acid (n = 10 348), or 10-mg enalapril alone (n = 10 354). All-cause mortality, a pr...
Source: Journal of Hypertension - April 26, 2017 Category: Cardiology Tags: ORIGINAL PAPERS: Kidney Source Type: research

Homocysteine and Stroke Risk Clinical Sciences
Conclusions—In Chinese hypertensive patients, the effect of homocysteine on the first stroke was significantly modified by the methylenetetrahydrofolate reductase C677T genotype and folic acid supplementation. Such information may help to more precisely predict stroke risk and develop folic acid interventions tailored to individual genetic background and nutritional status.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00794885.
Source: Stroke - April 24, 2017 Category: Neurology Authors: Min Zhao, Xiaobin Wang, Mingli He, Xianhui Qin, Genfu Tang, Yong Huo, Jianping Li, Jia Fu, Xiao Huang, Xiaoshu Cheng, Binyan Wang, Fan Fan Hou, Ningling Sun, Yefeng Cai Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

Association of Serum Uric Acid with Increased Risk of Cancer among Hypertensive Chinese
This study included 20577 adult hypertensive patients with valid SUA measurements who participated in the China Stroke Primary Prevention Trial where subjects were randomly assigned to receive a double‐blind treatment of either 10mg enalapril (n=10286) or 10.8mg enalapril‐folic acid (n=10291). Subjects were prospectively followed for a median of 4.5 years. Cox proportional hazards models were used to calculate hazards ratios (HR) of cancer risk associated with SUA. A total of 232 participants developed cancer. SUA was independently associated with increased cancer risk in the enalapril group [HR: 1.12, (95% CI: 1.03‐...
Source: International Journal of Cancer - April 10, 2017 Category: Cancer & Oncology Authors: Juan Yang, Yupeng Wang, Qianqian Zhao, Xianglin Zhang, Xiaobin Wang, Xianhui Qin, Rong Zhang, Lin Shen, Xiaodong Jiang, Hua Jiang, Yu Lei, Binyan Wang, Jin Gu, Fan Fan Hou, Yong Huo, Wei Gao, Xiping Xu Tags: Research Article Source Type: research

Folic acid therapy reduces serum uric acid in hypertensive patients: a substudy of the China Stroke Primary Prevention Trial (CSPPT) Vitamins, minerals, and phytochemicals
Conclusions: Enalapril–folic acid therapy, compared with enalapril alone, can significantly reduce the magnitude of the increase of UA concentrations in hypertensive adults. This trial was registered at clinicaltrials.gov as NCT00794885.
Source: American Journal of Clinical Nutrition - April 3, 2017 Category: Nutrition Authors: Qin, X., Li, Y., He, M., Tang, G., Yin, D., Liang, M., Wang, B., Nie, J., Huo, Y., Xu, X., Hou, F. F. Tags: Research Need: Role of Nutrition in Health Maintenance, Research Need: Role of Nutrition in Medical Management Vitamins, minerals, and phytochemicals Source Type: research

The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF
Conclusions Compared with enalapril, sacubitril/valsartan reduced the risk of both the primary endpoint and a coronary composite outcome in PARADIGM-HF. Additional studies on the effect of sacubitril/valsartan on atherothrombotic outcomes in high risk patients are merited.
Source: American Heart Journal - March 14, 2017 Category: Cardiology Source Type: research